Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

被引：5
|
作者：
Batlevi, Connie Lee [1 ]
Park, Steven I. [2 ]
Nastoupil, Loretta [3 ]
Phillips, Tycel [4 ]
Amengual, Jennifer E. [5 ]
Andorsky, David [6 ]
Campbell, Philip [7 ]
McKay, Pamela [8 ]
Pagel, John M. [9 ]
Leonard, John P. [10 ]
Yang, Jay [11 ]
O'Connor, Heather [11 ]
Hamlett, Anthony [11 ]
Adib, Deyaa [11 ]
Morschhauser, Franck [12 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
[3] MD Anderson Canc Ctr, Houston, TX USA
[4] Univ Michigan, Ann Arbor, MI USA
[5] Columbia Univ, Irving Med Ctr, New York, NY USA
[6] Rocky Mt Canc Ctr, Boulder, CO USA
[7] Univ Hosp Geelong, Barwon Hlth, Geelong, Vic, Australia
[8] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[9] Swedish Canc Inst, Ctr Blood Disorders & Stem Cell Transplantat, Seattle, WA USA
[10] Weill Cornell Med, New York, NY USA
[11] Epizyme Inc, Cambridge, MA USA
[12] Univ Lille, CHU Lille, EA 7365 GRITA Grp Rech Formes Injectables & Tec, F-59000 Lille, France
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-148199
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2207
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
    Batlevi, Connie Lee
    Park, Steven I.
    Phillips, Tycel Jovelle
    Amengual, Jennifer
    Andorsky, David Jacob
    Campbell, Philip
    Mckay, Pamela
    Leonard, John Paul
    Sondhi, Manu
    Yang, Jay
    Chen, Yingxue
    O'Connor, Heather
    Slatcher, Pamela
    Morschhauser, Franck
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] A Phase 1b/3 Randomized, Double-Blind, 3-Stage Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
    Leonard, John
    Batlevi, Connie Lee
    Gabrail, Nashat
    Pagel, John M.
    Yang, Jay
    Whalen, Jennifer
    Adib, Deyaa
    Morschhauser, Franck
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S279 - S279
  • [3] Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
    Batlevi, Connie Lee
    Salles, Gilles
    Park, Steven, I
    Phillips, Tycel J.
    Amengual, Jennifer E.
    Andorsky, David
    Campbell, Philip
    McKay, Pamela
    Leonard, John P.
    Sondhi, Manu
    Chen, Yingxue
    Slatcher, Pamela L.
    Lin, Richard
    Szanto, Attila
    Abbadi, Sara
    Morschhauser, Franck
    BLOOD, 2022, 140 : 2296 - 2298
  • [4] A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma
    Salles, Gilles
    Shah, Harsh
    Leonard, John P.
    Szanto, Attila
    Chen, Jade
    Bannerji, Rajat
    Morschhauser, Franck
    Nastoupil, Loretta J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S454 - S455
  • [5] LENALIDOMIDE PLUS RITUXIMAB IN ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 151 - 151
  • [6] A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
    Sehn, Laurie Helen
    Scholz, Christian W.
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Manzke, Oliver
    Seguy, Francis
    Li, Di
    Huebel, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up
    Salles, Gilles
    Park, Steven I.
    Phillips, Tycel J.
    Amengual, Jennifer E.
    Andorsky, David J.
    Campbell, Philip
    McKay, Pamela
    Leonard, John P.
    Chen, Yingxue
    Chen, Jade
    Bannerji, Rajat
    Kapopara, Apoorva
    Szanto, Attila
    Morschhauser, Franck
    BLOOD, 2023, 142
  • [8] Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
    Sehn, Laurie H.
    Luminari, Stefano
    Scholz, Christian W.
    Huebel, Kai
    Salar, Antonio
    Paneesha, Shankara
    Wahlin, Bjorn E.
    Panayiotidis, Panayiotis
    Lee, Hui-Peng
    Ubieto, Ana Jimenez
    Sancho, Juan-Manuel
    Kim, Tae Min
    Domenech, Eva Domingo
    Kumode, Takahiro
    Poh, Christina
    Thieblemont, Catherine
    Deeren, Dries
    de Wit, Edwin
    Arbushites, Michael
    Casadebaig, Marie-Laure
    Trneny, Marek
    BLOOD, 2024, 144 : LBA1 - LBA4
  • [9] A Phase II Study of Lenalidomide Plus Rituximab in Patients with Newly Diagnosed Follicular Lymphoma: An Interim Analysis
    Zheng, Zhong
    Wang, Li
    Cheng, Shu
    Xu, Pengpeng
    Zhao, Weili
    BLOOD, 2019, 134
  • [10] Pharmacokinetics, Drug Interaction, and Exposure-Safety Analyses of Tazemetostat When Co-Administered with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
    Chen, Yingxue
    Bannerji, Rajat
    Teng, Renli
    Szanto, Attila
    Ogier, Julien
    BLOOD, 2023, 142
12345